

Customer survey confirms strong symptom relief among VagiVital® users

Stockholm, 28th January, 2019 – Peptonic Medical (publ) ("Peptonic" or "Company") today announced that the results of a recently conducted survey among women that have used **VagiVital®** indicate a very strong treatment effect. Of more than two hundred respondents of the survey, three out of four reported symptom relief, regardless for how long they had used **VagiVital®**. Of those women who had used **VagiVital®** for two months or longer, nine out of ten reported symptom relief.

The survey was performed during the period of December 2018 to mid January 2019.

- *These results are of course very encouraging and effectively verify the results of the **VagiVital®** clinical study, that is, that the product provides strong symptom relief to those suffering from vaginal atrophy and dryness, says Dr Johan Inbarr, CEO of Peptonic Medical. This explains the good reception of the product among users and the increasing repurchase rates.*

Respondents also agreed that the applicator is easy to use and that the instructions for use are easy to follow. A vast majority of the respondents would 'most likely' recommend **VagiVital®** to a friend.

All answers have been treated anonymously.

For more information, please contact;

Johan Inbarr, CEO

Mobile: +46 708 853 893

E-mail: johan.inbarr@peptonicmedical.se

This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 28th January 2019.

About VagiVital®

VagiVital® is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.

VagiVital® was launched in Sweden as a non-prescription self-care product in July 2018 (see www.vagivital.com).

About Peptonic Medical

Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.

VagiVital® is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.

Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlight.se, ticker: PMED) in Stockholm, Sweden.

For more information: www.peptonicmedical.com